Digital most cancers care firm Kaiku Health has entered right into a strategic partnership with pharma and diagnostics large Roche to supply Kaiku’s instruments for symptom administration and help to clinics and sufferers.
Finnish-born Kaiku supplies a digital platform the place sufferers can enter their signs as they bear most cancers remedy, obtain suggestions for lower-acuity issues and preserve the care crew knowledgeable to allow them to intervene and supply help when crucial.
The businesses stated their long-term aim is to develop and supply extra digital well being instruments “by way of a multi-partner ecosystem,” in addition to advocate for reimbursement for monitoring and administration platforms.
“Kaiku Well being and Roche share a dedication to make personalised healthcare obtainable for extra sufferers by way of digital options. Collectively we have now already developed remedy and product-specific modules in most cancers immunotherapy and different focused therapies,” Kaiku CEO and cofounder Lauri Sippola stated in a press release.
“Now we’re excited to take our partnership additional and to increase the attain of digital affected person monitoring and administration when it comes to geography, and throughout new therapies and most cancers sorts, for a rising variety of sufferers.”
WHY IT MATTERS
This is not Kaiku’s first pharma partnership. A few 12 months in the past, the corporate teamed up with Novartis to monitor and manage melanoma, a kind of pores and skin most cancers. Earlier than the corporate was acquired by Swedish oncology company Elekta in 2020, it partnered with Amgen to supply digital symptom-tracking for a number of myeloma, a kind of bone marrow most cancers.
Roche is pitching the collaboration as a method to enhance care and outcomes for most cancers sufferers.
“Digital options have gotten more and more necessary for delivering high quality care to sufferers. This partnership is a big step towards delivering digital affected person monitoring and administration options that will assist enhance outcomes equivalent to symptom burden and high quality of life for people receiving systemic remedy for most cancers,” Dr. James Sabry, world head of pharma partnering at Roche, stated in a press release.
THE LARGER TREND
Digital well being and pharma partnerships aren’t unusual. Final week, prescription digital therapeutics startup MedRhythms entered into a licensing agreement with Biogen to develop and commercialize its MR-004 product, which goals to deal with gait deficits in individuals with a number of sclerosis.
In January, Swedish startup Alex Therapeutics entered into a strategic commercial partnership with Pfizer to construct digital therapeutics for nicotine dependancy. Alex, which recently raised €3.5 million, presents a platform made to assist pharma and life science companions create and launch digital therapeutics.
Different firms within the digital most cancers care and prevention house embrace Jasper Well being, which introduced a $25 million Series A raise in February. Reimagine Care, which focuses on providing in-home care, additionally recently scored $25 million. CancerIQ, which goals to find out a person affected person’s most cancers danger, introduced a $14 million Series B in March.